Scd1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| **SCD1 Protein** | |
|---|---|
| **Full Name** | Stearoyl-CoA Desaturase 1 |
| **Gene** | SCD1 |
| **UniProt ID** | O00767 |
| **Molecular Weight** | 60 kDa |
| **Subcellular Localization** | Endoplasmic Reticulum |
| **Protein Family** | Stearoyl-CoA Desaturase Family |
SCD1 (stearoyl-CoA desaturase 1) is the rate-limiting enzyme that introduces a cis-double bond at the delta-9 position of saturated fatty acids, converting stearoyl-CoA to oleoyl-CoA. This enzyme plays a critical role in lipid metabolism and membrane composition, and its dysregulation has been implicated in multiple neurodegenerative diseases [PMID: 31135089].
SCD1 is an integral ER membrane protein approximately 360 amino acids in length. The structure contains:
Six Transmembrane Domains : Span the ER membrane in an alternating topology [PMID: 18685521]Diiron Center : The catalytic center contains a non-heme iron cofactor required for desaturation [PMID: 19481183]Active Site : Substrate binding pocket that accommodates fatty acyl-CoA substratesN-terminal Cytoplasmic Domain : Contains regulatory sequences and the catalytic core
The enzyme exists as a homodimer, with dimerization being essential for catalytic activity [PMID: 20823477].
SCD1 catalyzes the rate-limiting step in monounsaturated fatty acid (MUFA) synthesis:
Desaturation Reaction : Converts saturated fatty acids (stearoyl-CoA, 18:0) to monounsaturated fatty acids (oleoyl-CoA, 18:1Δ9) [PMID: 19481183]Membrane Fluidity : Produces oleic acid essential for phospholipid composition and membrane fluidity [PMID: 20823477]Lipid Droplet Regulation : Affects triglyceride storage and lipid droplet biogenesis [PMID: 30649823]Insulin Sensitivity : Modulates insulin signaling through changes in membrane lipid composition [PMID: 19179061]Energy Storage : Facilitates triglyceride synthesis for energy storage
SCD1 preferentially desaturates:
Stearoyl-CoA (18:0) → Oleoyl-CoA (18:1)
Palmitoyl-CoA (16:0) → Palmitoleoyl-CoA (16:1)
The enzyme has lower activity toward longer chain fatty acids.
SCD1 expression and activity are tightly regulated:
Transcriptional : SREBP-1c is the major transcriptional activatorNutritional : Upregulated by carbohydrates and downregulated by fastingHormonal : Insulin stimulates SCD1 expressionFeedback : Product inhibition by oleoyl-CoA
SCD1 dysregulation plays multiple roles in AD pathogenesis [PMID: 31135089]:
Amyloid Processing : Altered membrane lipid composition affects amyloid precursor protein (APP) processing and Aβ generation [PMID: 30649823]ER Stress : SCD1 dysfunction contributes to endoplasmic reticulum stress, a feature of AD neuronsMembrane Fluidity : Changes in neuronal membrane fluidity affect synaptic function and neurotransmitter releaseInflammation : Altered fatty acid metabolism affects neuroinflammation through eicosanoid productionMitochondrial Function : Lipid composition affects mitochondrial membranes and function
Dopaminergic Neurons : SCD1 activity affects survival of dopaminergic neurons in the substantia nigra [PMID: 31135089]Alpha-Synuclein Mitochondrial Dysfunction : SCD1 alterations compound mitochondrial dysfunction in PD
Lipid Metabolism : Altered SCD1 expression observed in ALS motor neuronsEnergy Metabolism : Changes in fatty acid desaturation affect neuronal energy homeostasisER Stress : SCD1 dysfunction contributes to ER stress, a key pathway in ALS pathogenesis
Transcriptional Dysregulation : Mutant huntingtin affects SCD1 expressionMetabolic Changes : Altered lipid metabolism is an early feature of HDNeuronal Function : Changes in membrane composition affect neuronal excitability
SCD1 is a therapeutic target for metabolic diseases, but brain-penetrant inhibitors for neurodegeneration are still in development [PMID: 31135089]:
Blood-Brain Barrier Essential Function : Complete inhibition may have adverse effects due to essential nature of oleic acidTiming : Intervention may need to be early in disease course
Brain-Penetrant Inhibitors : Development of BBB-permeable SCD1 modulatorsPartial Inhibition : Low-dose or intermittent inhibition may provide benefitsCombination Therapy : SCD1 modulation combined with other approaches
Dietary Modification : Omega-3 fatty acid supplementationTargeting Downstream Pathways : Focus on downstream effects of SCD1 dysregulation
SCD1 activity may serve as a biomarker:
Blood SCD1 : Peripheral SCD1 activity reflects metabolic statusCSF Fatty Acid Ratio : Saturated/unsaturated ratio in CSF may indicate CNS SCD1 activityImaging : PET probes for lipid metabolism are under development
Dutta K et al. (2019). SCD1 and neurodegeneration. J Neurosci Res . PMID:31135089 - Demonstrates SCD1 dysregulation in AD and PD models.
Flowers MT et al. (2008). The role of SCD1 in metabolic disease. Curr Opin Lipidol . PMID:18685521 - Reviews SCD1 function and therapeutic potential.
Miyazaki M et al. (2009). Stearoyl-CoA desaturase enzymes. Prostaglandins Leukot Essent Fatty Acids . PMID:19179061 - Catalytic mechanism and regulation.
Dobrzyn P et al. (2010). Role of SCD1 in lipid metabolism. Adv Nutr . PMID:20823477 - Metabolic functions and regulation.
Liu X et al. (2019). SCD1 in neurodegeneration. J Neurochem . PMID:30649823 - SCD1 in Alzheimer's disease pathogenesis.
The study of Scd1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Paton CM, et al. (2009). SCD1 and metabolic disease. Physiol Behav . PMID:19481183
Dobrzyn P, et al. (2010). Role of SCD1 in lipid metabolism. Adv Nutr . PMID:20823477
Liu X, et al. (2019). SCD1 in neurodegeneration. J Neurochem . PMID:30649823
Miyazaki M, et al. (2009). Stearoyl-CoA desaturase enzymes. Prostaglandins Leukot Essent Fatty Acids . PMID:19179061
Ntambi JM, et al. (2002). Stearoyl-CoA desaturase 1. J Mol Neurosci . PMID:12108484
Brown JM, et al. (2008). SCD1 and metabolic syndrome. J Lipid Res . PMID:18316264
Sampath H, et al. (2009). SCD1 and insulin resistance. Cell Metab . PMID:19387414
Cohen P, et al. (2018). SCD1 as therapeutic target. Nat Rev Drug Discov . PMID:30542210
Hashimoto T, et al. (2020). SCD1 and ER stress in neurons. Cell Death Dis . PMID:32029725
Wang J, et al. (2021). SCD1 in tau pathology. Acta Neuropathol Commun . PMID:33849582